Nordic Life Science 1
CEO of SAGA Diagnostics CEO of BioLamina Head of
Clinical Development at Anocca PETER COLLINS joins SAGA after executive roles at major players in the liquid biopsy field, such as at Inivata as Chief Business Officer and at Guardant Health as VP Biopharma Business Development, as well as CBO of Yourgene. He was also VP, Head of Diagnostics at GSK for five years. “SAGA has a diverse and exceptionally talented team already in place. I’m excited to lead this next phase of growth, build out the team further, and execute on a strategy to rapidly bring our technologies into the clinics to benefit more people living with cancer,” says Collins. Founding CEO Lao Saal has been appointed Chief Operating Officer and remains a member of the Board of Directors. “In my new role as COO, I will be supporting Peter Collins, the wider SAGA team and our Board to deliver on our vision to make SAGA’s technologies available to as many cancer patients as possible and truly make a difference to people’s lives,” says Saal. 30 NORDICLIFESCIENCE.ORG VERONICA BYFIELD SKÖLD holds an MSc in Industrial Engineering and Business Management from the Royal Institute of Technology in Stockholm, Sweden, and she spent the first years of her career at management consulting firm the Boston Consulting Group. She has held several management positions in companies including Gambro, Elekta, and Permobil, heading up activities within strategy, marketing, commercialization, and medical affairs across global organizations. Most recently she spent four years as an investment partner at the Nordic healthcare investment firm Impilo. “Since joining the Board of Directors in early 2021, I have gradually got to know the market, company and team better, and I have seen the tremendous growth and all the opportunities that lie ahead of us. I am very excited to join this highly competent team and work jointly to advance the success of BioLamina and our customers,” says Byfield Sköld. CEO of Oncopeptides SANDRA BEVAN BRINGS 25 years’ experience in strategic and operational global drug development from Pharmaceutical and Biotech companies. She served 17 years at AstraZeneca in global clinical development and cross-functional project management positions. For the past eight years she has been the owner and Senior Pharmaceutical Development Consultant at Bevan Consulting AB. One of her core strengths is building and leading clinical teams, in all phases of clinical development, according to Anocca. She received her MSc in Health Sciences from the University of York, UK. Prior to joining the industry, she worked as a registered nurse in the UK’s NHS. “It is a real pleasure and an inspiring opportunity to join Anocca, and I’m looking forward to using my experience to take Anocca’s unique innovative approach to deciphering T-cell immunity towards clinical development,” says Bevan. JAKOB LINDBERG replaces Marty J Duvall, who has been the CEO since July 1, 2020. The leadership change follows the withdrawal of Pepaxto from the US market and the company’s need to focus its resources on research and development on the path ahead. “Jakob’s unique understanding of the platform technology and drug development will serve the company well for this phase and the journey ahead of us,” says Per-Wold Olsen, Chairman, Oncopeptides. “I would also like to thank Marty for his relentless focus on commercializing Pepaxto in the US. Unfortunate circumstances led us to where we are and we wish Marty all the best as he pursues new career options outside of Oncopeptides.” Lindberg was the CEO of Oncopeptides from the restart of the company in 2011, until June 2020. He has been instrumental in the development of Oncopeptides, and was previously the company’s Chief Scientific Officer. PHOTO PATRICK DEGERMAN PHOTO LIZA SIMONSSON